Immunovant, Inc. (IMVT)
NasdaqGS · USD · Healthcare · Biotechnology
$28.17 (-0.84%) as of
Key statistics
- Market cap
- 5.82B
- Forward P/E
- -10.24
- EPS (TTM)
- -2.82
- Dividend yield
- 0.00%
- 52-week range
- 19.21 – 45.42
- Beta
- 0.84
- Profit margin
- 0.00%
- Analyst target
- $48.88
- Volume
- 1.20M
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Durham, NC, United States
- Employees
- 315
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.